Medications not yet evaluated by P&T are considered NON-FORMULARY. Always check 2 unique patient identifiers - NAME and DATE OF BIRTH - at every step!
Please be sure to document all clinical activities daily.
Search results for:

tremelimumab

tremelimumab
Drug Name Form Strength Formulary Unrestricted Formulary Restricted Non-Formulary Interchange
Imjudo INJECTION, INTRAVENOUS 300 mg/15 mL      
Comments:

Formulary, restricted to oncologist use in the outpatient setting. Other first-line regimens should be attempted prior to the use of tremelimumab if possible. May be utilized as PAP.

 

 

Reviewed: March 2025

 

Tremelimumab (Imjudo) Spotlight

Last updated: Apr. 11, 2025






This site is intended for the staff of Huntsville Hospital.
While others may view accessible pages, Huntsville Hospital makes no warranty, express or implied,
as to the use of this information outside of Huntsville Hospital.
Please note than many documents are accessible via the provided link
only when connected to the Huntsville Hospital intranet.

Copyright © 2026 Rpharmy, LLC ­ All Rights Reserved